Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension

The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance

The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including amino-terminal brain natriuretic propeptide (NT-proBNP), and World Health Organization (WHO) functional class

Sotatercept was generally well tolerated in the trial and adverse events were consistent with previously published data on sotatercept in other diseases

Conference call and webcast with guest pulmonary key opinion leaders were held on, Monday, January 27th at 5:00 p.m. EST

Read more about their findings here

Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension